We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us


PerkinElmer provides detection technologies to detect and identify diseases, imaging technologies to help visualize s... read more Featured Products: More products

Download Mobile App

EUROIMMUN Launches SARS-CoV-2 Test System to Detect T-Cell Response

By LabMedica International staff writers
Posted on 15 Jan 2021
Print article
EUROIMMUN, a PerkinElmer, Inc. (Waltham, MA; USA) company, has launched a SARS-CoV-2 Interferon Gamma Release Assay (IGRA) for Research Use Only (RUO) to determine the activity of T-cells reactive to SARS-CoV-2, the pathogen causing COVID-19.

Evidence suggests that both pillars of the immune system, antibody and T-cell response, are important in understanding immunity against SARS-CoV-2 reinfections. IgG antibodies against the S1 subunit of the SARS-CoV-2 spike protein and specific long-lived T-cells are suspected to play the most relevant roles in virus neutralization and sustained immunity.

This novel IGRA uses whole blood samples for determination of T-cell activity against SARS-CoV-2 through detection of interferon gamma, an important signaling molecule of the immune system which is released by the T-cells upon contact with the virus. The detection system is based on the well-established ELISA technology and can be processed manually or automatically in most laboratory settings. For this reason, the assay can be a helpful tool in research studies evaluating the cellular immune response in SARS-CoV-2 infected or vaccinated individuals.

The IGRA for RUO is the latest addition to EUROIMMUN’s comprehensive SARS-CoV-2-specific product portfolio, which includes real-time PCR tests, an antigen detection assay and multiple antibody tests, a dried blood spot solution, as well as automation systems for small, medium and high sample throughput.

“There are still a lot of open questions with respect to the COVID-19 disease progression and the development of long-term immunity after infection or vaccination,” said Dr. Wolfgang Schlumberger, CEO of EUROIMMUN. “In order to help answer these questions, both the IGRA and our Anti-SARS-CoV-2 QuantiVacTM ELISA (IgG) allow researchers to study the immune response to the coronavirus much more comprehensively and broadly to learn about vaccine efficacy from different angles.”

Gold Supplier
Respiratory Panel with SARS-CoV-2
BioFire Respiratory 2.1-EZ (RP2.1- EZ) Panel With SARS-CoV-2
COVID-19 IgM/IgG Test
DPP COVID-19 IgM/IgG System
COVID-19 and Influenza Test
COVID-19 and Influenza A+B Antigen Combo Rapid Test
Nucleic Acid Purification Kit
Maxwell RSC Viral Total Nucleic Acid Purification Kit

Print article


Molecular Diagnostics

view channel
Image: Histopathologic image from a patient with Li Fraumeni syndrome showing accumulation of mutant TP53 in tumoral cells (Photo courtesy of Thierry Soussi, PhD).

Clinical Germline Testing Evaluated for Pediatric Cancer Patients

Pediatric cancer is rare, with fewer than 10,000 solid tumors diagnosed in children annually in the USA. Previous studies interrogating germline predisposition broadly across pediatric cancer types have... Read more


view channel

Mindray and Tencent AI Lab to Jointly Develop AI Products for Blood Disease Screening and In Vitro Diagnosis

Shenzhen Mindray Biomedical Electronics Co., Ltd. (Shenzhen, China) has signed an AI cooperation framework agreement with Tencent AI Lab (Shenzhen, China) to jointly develop AI products for blood cell... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.